Dr. Anjali Rohatgi, M.D., Ph.D.

Claim this profile

Washington University School of Medicine

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
1 reported clinical trial
2 drugs studied

Area of expertise

1Lung Cancer
Anjali Rohatgi, M.D., Ph.D. has run 1 trial for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
EGFR positive
2Non-Small Cell Lung Cancer
Anjali Rohatgi, M.D., Ph.D. has run 1 trial for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
EGFR positive

Affiliated Hospitals

Image of trial facility.
Washington University School Of Medicine

Clinical Trials Anjali Rohatgi, M.D., Ph.D. is currently running

Image of trial facility.

APL-101 + Osimertinib

for Non-Small Cell Lung Cancer

In this study, patients with metastatic non-small cell lung cancer that is EGFR-mutated, who have received at least 8 and not more than 12 weeks of treatment with osimertinib without demonstrating disease progression, will receive APL-101 in combination with osimertinib until progression. Dosing of APL-101 will be escalated until the maximum tolerated dose is determined, at which point 10 additional patients will be enrolled at that dose in the expansion cohort.
Recruiting1 award Phase 1 & 28 criteria

More about Anjali Rohatgi, M.D., Ph.D.

Clinical Trial Related3 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Anjali Rohatgi, M.D., Ph.D. has experience with
  • APL-101
  • Osimertinib
Breakdown of trials Anjali Rohatgi, M.D., Ph.D. has run
Lung Cancer
Non-Small Cell Lung Cancer

Other Doctors you might be interested in

Justin Barnes, M.D.Washington University School of Medicine
Thomas Maddox, MDWashington University School of Medicine
Angela Hirbe, M.D., Ph.D.Washington University School of Medicine

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anjali Rohatgi, M.D., Ph.D. specialize in?
Anjali Rohatgi, M.D., Ph.D. focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Anjali Rohatgi, M.D., Ph.D. currently recruiting for clinical trials?
Yes, Anjali Rohatgi, M.D., Ph.D. is currently recruiting for 1 clinical trial in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Anjali Rohatgi, M.D., Ph.D. has studied deeply?
Yes, Anjali Rohatgi, M.D., Ph.D. has studied treatments such as APL-101, Osimertinib.
What is the best way to schedule an appointment with Anjali Rohatgi, M.D., Ph.D.?
Apply for one of the trials that Anjali Rohatgi, M.D., Ph.D. is conducting.
What is the office address of Anjali Rohatgi, M.D., Ph.D.?
The office of Anjali Rohatgi, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top